The producers of aducanumab are offered 6‐12 months acceptance from the FDA to offer proof of clinical reward. Rules for its suitable use are beginning to be revealedInsomnia could partly mediate melancholy risk for Alzheimer's and similar dementias through beta‐amyloid accumulation, tau protein aggregation, inflammation and blood‐Mind‐barr